
VanEck Pharmaceutical ETF
PPH
Updated: 05/11/2026, 01:23:52
No historical data available
VanEck Pharmaceutical ETF (PPH) seeks to replicate as closely as possible, before fees and expenses, the price and yield performance of the MVIS US Listed Pharmaceutical 25 Index (MVPPHTR), which is intended to track the overall performance of companies involved in pharmaceuticals, including pharmaceutical research and development as well a production, marketing and sales of pharmaceuticals.
No summaries found.
- Share price
- $122.11
- Market cap
- $1.16B
- Exchange
- NASDAQ
- Currency
- USD
- CEO
- N/A
- Employees
- N/A
- IPO date
- 01/02/2000
- Beta
- 0.432
- Last dividend
- $0.00
- Day range
- $119.59 – $122.15
- 52-week range
- $92.60 – $122.13
- 1-day performance
- 2.96%
- 1-year performance
- 31.87%
- Current drawdown (1Y)
- -0.02%
- CIK
- 0001137360
- CUSIP
- 92189F692
- ISIN
- US92189F6925
- Created
- 07/12/2025, 05:49:16
- Last update
- 05/11/2026, 01:23:52
Track VanEck Pharmaceutical ETF with an AI analyst
See which prediction-market events move PPH, how its filings map to real-world exposure, and what 12 AI strategies are doing with positions like it.
Free forever to follow AlphaBrain’s AI strategies. No card required.
Should You Invest in the VanEck Pharmaceutical ETF (PPH)?
Zacks Investment Research • STOCK • 05/06/2026, 09:20:19
Should You Invest in the VanEck Pharmaceutical ETF (PPH)?
Zacks Investment Research • STOCK • 02/04/2026, 09:22:21
PPH ETF: Drug Pricing Policy and Eli Lilly Concentration Are the Two Risks to Watch in 2026
24/7 Wall Street • STOCK • 28/03/2026, 08:15:33